» Non-Financial

Company Directors
Company Advisors
New & Press Releases
Directors Share Dealings
Major Shareholders
Company Subsidiary Calendar of Future Events
Company Name Change
Company Status Change

» Analyst Spreadsheet

Quick View(PDF)
Trader(PDF)
Dossier(PDF)
Download Analyst Template
Analyst Spreadsheet
Download Master Template
Annual Master Spreadsheet
Quarterly Master Spreadsheet
Annual & Quaterly Master Spreadsheet
Valuation Model Template
Valuation Model Spreadsheet
Business Risk(PDF)
Credit Metrics(PDF)
Annual Reports

For all products and/or service inquiries or to learn more about how WVB customer service solutions can reduce your service costs while increasing customer satisfaction, email us at .

FINCH THERAPEUTICS GROUP

WVB Number : USA000071016 Country : United States of America
SIC categorization : BIOLOGICAL PDS,EX DIAGNSTICS (2836) ISIN : US31773D1019
FT categorization : HEALTH CARE (431)  
Company status: ACTIVE  

» Corporation Profile :

Profile in brief:
The Company is a clinical-stage microbiome therapeutics Company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.
Phone : 1 Fax :
Chairman: : N/A Auditor : DELOITTE & TOUCHE LLP
CEO/Managing Director : MARK SMITH

» Company Facts

Net Profit Margin (%) -509.66  
Operating Margin (%) -509.66  
Return on Assets (%) -29.26  
Return on Equity (%) 50.68  
Employees N/A  

» Company Financials

  Annual (2020)
Income Statement
('000 USD )
Sales/Total Revenue 7,719  
EBITDA -38,636  
EBIT -39,447  
Net Income -39,341  
Balance Sheet
( '000 USD)
Total Current Assets 106,164  
Total Assets 165,338  
Current Liabilities 11,486  
Total Liabilities & Debt 28,002  
Total Equity -95,718  
Cash & Flow
( '000 USD)
Net Income/Staring Line -39,341  
Cash from Operating -31,329  
Cash from Investing -2,633  
Cash from Financing 91,475  
Cash & Equivalent Yr End 99,909